APLS - Apellis Pharmaceuticals Inc
IEX Last Trade
38.87
0.150 0.386%
Share volume: 636,076
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$38.72
0.15
0.39%
Fundamental analysis
23%
Profitability
25%
Dept financing
17%
Liquidity
50%
Performance
15%
Performance
5 Days
-3.02%
1 Month
-0.84%
3 Months
-4.54%
6 Months
-39.27%
1 Year
-4.21%
2 Year
-33.89%
Key data
Stock price
$38.87
DAY RANGE
N/A - N/A
52 WEEK RANGE
$33.49 - $73.80
52 WEEK CHANGE
-$0.11
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Cedric Francois
Region: US
Website: http://apellis.com/
Employees: 794
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://apellis.com/
Employees: 794
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Recent news